Arena Pharmaceuticals

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. The Company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1977
Size (employees)
106 (est)-53%
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US

Arena Pharmaceuticals Office Locations

Arena Pharmaceuticals has offices in San Diego and Zofingen
San Diego, US (HQ)
6154 Nancy Ridge Drive
Zofingen, CH
4 Untere Brühlstrasse

Arena Pharmaceuticals Data and Metrics

Arena Pharmaceuticals Financial Metrics

Arena Pharmaceuticals's revenue was reported to be $6.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

6.6 m

Gross profit (Q1, 2017)

4.1 m

Gross profit margin (Q1, 2017), %

62%

Net income (Q1, 2017)

(22.5 m)

EBIT (Q1, 2017)

(20.5 m)

Market capitalization (22-Aug-2017)

635.4 m

Cash (31-Mar-2017)

79.5 m
Arena Pharmaceuticals's current market capitalization is $635.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

81.4 m37 m38.3 m124 m

Revenue growth, %

(55%)4%223%

Cost of goods sold

1.8 m6.4 m8.6 m9.3 m

Gross profit

79.6 m30.6 m29.7 m114.7 m

Gross profit Margin, %

98%83%78%93%

EBIT

(22.9 m)(105.3 m)(103.2 m)(17.1 m)

EBIT margin, %

(28%)(285%)(269%)(14%)

Interest income

89 k83 k158 k290 k

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

12.8 m8.2 m12.3 m9.2 m9.1 m9.8 m9.5 m19.2 m6.6 m

Cost of goods sold

1.5 m1.8 m3.2 m1.3 m1.6 m2.4 m851 k882 k2.5 m

Gross profit

11.3 m6.4 m9.1 m7.9 m7.5 m7.4 m8.7 m18.4 m4.1 m

Gross profit Margin, %

89%79%74%86%82%75%91%95%62%

R&D expense

27 m24.5 m22 m24.2 m22.1 m18.5 m18.5 m17.5 m15.5 m

General and administrative expense

9.1 m8 m8.4 m8.8 m9 m6.9 m8.5 m8.6 m8.2 m

Operating expense total

36.2 m32.5 m30.4 m33 m31.1 m25.4 m27 m26.1 m23.7 m

EBIT

(25.4 m)(26.2 m)(21.7 m)(27 m)(25.2 m)(19.2 m)(26.2 m)(9.9 m)(20.5 m)

EBIT margin, %

(198%)(321%)(177%)(294%)(276%)(195%)(276%)(51%)(310%)

Interest expense

1.7 m1.7 m1.7 m1.8 m1.7 m1.7 m1.6 m1.6 m1.6 m

Interest income

24 k16 k34 k34 k37 k88 k105 k54 k34 k

Net Income

7.5 m(10.7 m)(24.3 m)(26.8 m)(26.4 m)(21.5 m)(27.2 m)(12.5 m)(22.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

221.9 m163.2 m156.2 m90.7 m

Accounts Receivable

10.6 m3.7 m4.9 m20.2 m

Inventories

3.6 m4.1 m4.2 m6.7 m

Current Assets

248.8 m181.9 m174.8 m119.9 m

Total Assets

339.8 m276.4 m256.8 m169 m

Accounts Payable

1.5 b

Current Liabilities

70.7 m67.4 m49.9 m63.9 m

Additional Paid-in Capital

1.3 b1.3 b1.4 b1.4 b

Retained Earnings

(1.2 b)(1.3 b)(1.4 b)(1.4 b)

Total Equity

91.9 m47.3 m53.5 m40.4 m

Financial Leverage

3.7 x5.8 x4.8 x4.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

200.8 m188.3 m241 m216.7 m181.3 m139.5 m122 m101.6 m79.5 m

Accounts Receivable

7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m

Inventories

12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m

Current Assets

243.7 m209.1 m268.6 m236 m200.2 m160.1 m139.8 m134.9 m92.3 m

Total Assets

334.7 m296.7 m362.3 m329.1 m286.1 m241.4 m217.8 m210.2 m139.8 m

Current Liabilities

61.3 m56 m74.4 m61.9 m47.6 m50.5 m54.6 m60.5 m49.8 m

Common Stock

22 k22 k24 k24 k24 k24 k24 k24 k24 k

Additional Paid-in Capital

1.3 b1.3 b1.4 b1.4 b1.4 b1.4 b1.4 b1.4 b1.4 b

Retained Earnings

(1.2 b)(1.2 b)(1.3 b)(1.3 b)(1.3 b)(1.4 b)(1.4 b)(1.4 b)(1.4 b)

Total Equity

102.8 m76.3 m128.9 m107.4 m82.2 m37.6 m13.6 m4.1 m26.7 m

Financial Leverage

3.3 x3.9 x2.8 x3.1 x3.5 x6.4 x16.1 x51.6 x5.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)

Depreciation and Amortization

7.7 m8.7 m9.8 m9.1 m

Accounts Receivable

(4.5 m)6.4 m(1.4 m)(15.9 m)

Inventories

(6.1 m)870 k1.9 m3.2 m

Cash From Operating Activities

72.8 m(101.4 m)(98.1 m)(62.1 m)

Cash From Investing Activities

(8.7 m)40.9 m(8.2 m)(750 k)

Cash From Financing Activities

1.7 m3.2 m101.1 m(2.3 m)

Interest Paid

7 m6.8 m6.6 m6.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

7.5 m(10.7 m)(24.3 m)(26.8 m)(26.4 m)(21.5 m)(27.2 m)(12.5 m)(22.5 m)

Accounts Receivable

7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m

Inventories

12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m
USDY, 2017

Revenue/Employee

39.7 k

Financial Leverage

5.2 x

Arena Pharmaceuticals Market Value History

Traffic Overview of Arena Pharmaceuticals

Arena Pharmaceuticals Company Life and Culture

You may also be interested in